Weekly Checkup
November 20, 2026
The U.S. Loses Its Measles Elimination Status
After almost three decades, the United States has lost its measles elimination status. Allowing a vaccine-preventable disease such as measles to regain a foothold in the United States is an obvious public health failure. But keeping measles under control was not simply a medical achievement; it spared patients, health care providers, employers, and taxpayers substantial costs.
The designation, first achieved in 2000, was revoked after the Pan American Health Organization determined that sustained domestic transmission has returned. According to the Centers for Disease Control and Prevention (CDC), the United States has recorded 5,412 confirmed measles cases in 2026 as of November 12, more than double the 2,289 reported throughout 2025.
The American Action Forum has previously examined the economics of measles outbreaks, particularly the substantial difference between preventing infection through vaccination and managing its consequences. The 2025 Texas outbreak, which resulted in 762 cases, 99 hospitalizations, and two deaths, generated an estimated $35.4 million in combined medical expenses, lost productivity, and public health response costs. A subsequent analysis of South Carolina’s outbreak, which had reached 993 cases at the time of calculation, estimated approximately $35.5 million in similar costs. By comparison, vaccinating an equivalent number of children through the Vaccines for Children program would have cost approximately $40,000 and $66,000, respectively. These figures are estimates rather than audited expenditures, and the vaccination comparisons do not reflect the full cost of achieving community-wide protection. Still, they illustrate just how much more expensive it can be to manage measles than to prevent it.
New research reinforces this argument. A study published in Vaccine examined outbreak costs across 18 states and estimated that initiating a public health response to measles carries approximately $298,000 in fixed costs, followed by roughly $16,300 for each additional case. These costs reflect the barrage of resources needed to identify exposures, trace contacts, coordinate vaccination campaigns, and contain transmission. Parents missed work, and health care providers diverted resources toward managing a preventable disease.
The longer-term economic outlook is more concerning. The Proceedings of the National Academy of Sciences modeled the economic consequences of continued declines in measles, mumps, and rubella (MMR) vaccination coverage. Under a scenario in which coverage among children ages zero to six falls by one percentage point annually, researchers projected that the annual economic burden of measles could reach approximately $1.5 billion by 2030, with cumulative costs of $7.8 billion over five years. These are modeled estimates rather than predictions of actual expenditures, but they demonstrate how even modest reductions in vaccination coverage could produce disproportionately large costs. Direct medical expenditures accounted for only a small fraction. The researchers estimated that outbreak response activities accounted for roughly 65 percent of measles-related economic costs, while lost productivity represented another 32 percent.
Those projections are particularly troubling given existing vaccination trends. CDC data show that national MMR coverage among kindergartners has fallen from 95.2 percent during the 2019–2020 school year to 92.4 percent in 2025–2026, leaving approximately 280,000 kindergartners at risk. As the number of susceptible individuals grows, so does the risk of sustained transmission and the need for repeated, expensive interventions. The resources devoted to containing outbreaks could instead support other health care and public health priorities.
The United States already has the most important tool for reversing this trend and preventing the spread of measles. The MMR vaccine regimen is approximately 97 percent effective against measles, and longstanding immunization programs make vaccination broadly available with little or no patient cost-sharing. Yet access alone does not guarantee uptake, and federal leadership has not consistently reinforced established, scientifically backed vaccination practices. Declining vaccination rates preceded this administration, but that is no reason for federal leaders to equivocate about the value of routine vaccination or introduce uncertainty when coverage needs to improve. Confidence in vaccination desperately needs rebuilding, but the administration has promoted unfounded claims about vaccine safety, replaced longstanding scientific advisers, sought to narrow routine childhood immunization recommendations, and directed legal efforts against state vaccination requirements.
The loss of measles elimination status is a serious public health failure, but it also represents a broader economic setback. Every dollar and hour devoted to investigating exposures, managing quarantines, and treating preventable infections carries an opportunity cost. Immunization helps avoid hospitalization, reduces burden on caregivers, and preserves productivity. Vaccination is a clear alignment between improving health outcomes and reducing health expenditures, making the continued erosion of coverage all the more difficult to justify. Regaining elimination status will require a renewed commitment to prevention and avoiding that commitment is neither medically defensible nor economically prudent.





